177lu-psma-617 vs. cabazitaxel for mcrpc
Published 4 years ago • 356 plays • Length 3:41Download video MP4
Download video MP3
Similar videos
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
2:46
upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
1:41
psmaddition: 177lu-psma-617 plus standard of care vs soc alone in patients with mhspc
-
5:59
lupsma vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
0:51
therap trial of 177lu-psma-617 review | david vanderweele, md | asco22 prostate cancer updates
-
6:59
first results of therap trial
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment
-
5:51
lupsma vs cabazitaxel for metastatic castration-resistant prostate cancer
-
8:11
asco: lupsma vs cabazitaxel for castration-resistant prostate cancer